I will give a brief run down.
COVID-19
C19 was unexpected but Dr. Patterson surmised that leronlimab would work. 15 people treated under emergency designation by FDA. Expected mortality rate of 85% after 14-days. 4 out of ICU and off ventilators within 3 days. 1 discharged from hospital. All 15 showed marked improvement of immune system. 7-day data being tabulated as we speak and results will be sent to New England Journal of Medicine and/or Nature. Because of these spectacular (and improving results), the FDA approved a phase 2 trial for 75 mild-moderate cases and a phase 2b/3 trial for severe cases. They are also applying for emergency approval as they get more results.
Cancer
Dr. Patterson figured out the mechanism of action for breast cancer and the FDA approved a compassionate use study. Again, spectacular results and CYDY has applied for
Break Through Designation and could hear back any time. The FDA also approved a basket study for
22-solid tumor cancers and that study is ongoing. If they continue with similar results, they will likely file for BTD status as well.
HIV
The drug was originally used to treat HIV patients. Over 840 people have taken it for HIV over several years and there haven't been any adverse side effects. That's part of the reason the FDA allows CYDY to try leronlimab on a myriad of illnesses--the safety data is impeccable and they know the drug won't harm anyone. They have passed phase 3 for combination HIV therapy and are awaiting approval to file a BLA which the FDA will review and then approve for commercial use. They also have mono therapy for HIV which is a bigger opportunity.
There are other uses for the drug but I think you get the idea it's a potential blockbuster and has the chance to help many millions of sick people. The CEO is a poor communicator but it's about execution now. Anyone who asks whether they should buy now needs to read the above first. Any specific questions?
ETA: if you want read what I wrote originally (circa October '19), look for the oldest mention of "Cytodyn".